C4 Therapeutics announced the appointment of Leonard Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies. Dr. Reyno joins C4T from Pionyr Immunotherapeutics, where he most recently served as president, research & development and chief medical officer and led the company to advancing two novel therapeutics into the clinic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CCCC:
- C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
- C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
- C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights